• hCG, H3K27 Methylation, and CXCL10 in Decidua

  2026-08-14

  The reference study identifies a hormone–chromatin–chemokine pathway in which trophoblast-derived hCG increases EZH2-associated H3K27me3 at the CXCL10 promoter in human decidual stromal cells. This mechanism links placental signaling to reduced CD8 T-cell recruitment and provides a useful framework for studying epigenetic control of immune adaptation at the maternal–fetal interface.

• T7 RNA Polymerase for Precise In Vitro RNA Synthesis

  2026-08-14

  T7 RNA Polymerase is a recombinant enzyme expressed in E. coli that selectively transcribes DNA templates carrying a T7 promoter. Its defined promoter recognition supports in vitro RNA synthesis for research workflows, including RNA vaccine production, antisense RNA, and RNAi studies.

• Bestatin (Ubenimex): Mechanism & Research Guide

  2026-08-13

  Bestatin, also called Ubenimex, is a research aminopeptidase inhibitor with reported activity against cytosol aminopeptidase, aminopeptidase N, zinc aminopeptidase, and aminopeptidase B. Its effects are assay-dependent: a peer-reviewed fibrin-matrix model found enhanced endothelial tube formation, so Bestatin should not be labeled universally anti-angiogenic.

• Optimized GBA1 mRNA for Gaucher Disease Therapy

  2026-08-13

  The reference study develops a rationally optimized human GBA1 mRNA platform that improves glucocerebrosidase expression, durability, and lysosomal delivery. In cellular and mouse experiments, the mRNA–lipid nanoparticle system restored disease-relevant enzyme function, supporting further investigation of mRNA therapy as an alternative or complement to enzyme replacement and substrate reduction strategies.

• PNU 74654: Designing Better Wnt Assays

  2026-08-12

  PNU 74654 is a Wnt signaling pathway inhibitor for testing how β-catenin-dependent signals shape cell fate. This guide focuses on causal assay design, controls, and responsible interpretation across cancer research, stem cell research, and muscle biology.

• Praeruptorin A, DMT1, and Ferroptosis in DIC

  2026-08-12

  This study used a ferrous-ion probe to screen herbal small molecules and identified Praeruptorin A as an intervention candidate for doxorubicin-induced cardiomyopathy. The evidence connects Praeruptorin A with reduced DMT1 expression, lower cardiomyocyte Fe2+ overload, suppressed ferroptosis, improved cardiac function, and retained doxorubicin antitumor activity.

• ABT-263 (Navitoclax) Apoptosis Workflow

  2026-08-11

  Build more informative apoptosis assays with ABT-263 (Navitoclax), from dose-response screening to mitochondrial mechanism validation. This workflow also translates a senescence-selective study into practical controls without overstating what Navitoclax has demonstrated in non-cancer tissues.

• CD28–ARS2–PKM2 Axis in CD8+ T Cells

  2026-08-11

  Holling and colleagues identify a CD28–ARS2 signaling axis that reshapes alternative splicing of PKM in activated CD8+ T cells, favoring PKM2 over PKM1. The work connects costimulation, RNA processing, glucose-use flexibility, interferon-γ production, and antitumor effector activity through a mechanism that is distinct from canonical CD28–PI3K signaling.

• Cardiogreen: From Vascular Imaging to PDT

  2026-08-10

  Cardiogreen, also known as Indocyanine green, connects vascular diagnostics with near-infrared therapeutic research. This guide translates its optical properties into practical workflows for cardiac output measurement, liver blood flow assessment, ophthalmic angiography, and photothermal or photodynamic assays in cancer models.

• U0126-EtOH: MEK1/2 Inhibitor Workflows

  2026-08-09

  U0126-EtOH provides a practical way to interrogate MEK1/2-dependent ERK signaling across neuronal, inflammatory, and leukemia models. This guide translates pathway selectivity into executable workflows, assay controls, and troubleshooting decisions for oxidative stress research and mechanistic cell biology.

• Hexa-Acylated LPS and Cancer Immunotherapy Response

  2026-08-08

  A 2025 Nature Microbiology study identifies the structure of gut microbiota-derived lipopolysaccharide, rather than bacterial taxonomy alone, as a functional determinant of anti-PD-1 response. Patient metagenomics, immune assays, and mouse tumor experiments show that hexa-acylated LPS activates TLR4-dependent immunity and can enhance checkpoint blockade efficacy.

• AZD8055: Practical mTOR Inhibitor Guide

  2026-08-07

  AZD8055 is an ATP-competitive mTOR inhibitor for examining mTORC1 and mTORC2 signaling in cellular and preclinical models. It is suited to mechanistic cancer and metabolic research, but should not be used as evidence of clinical efficacy or where aqueous solubility is required.

• AZD6482: Selective PI3Kβ Inhibitor for Metabolic and Platele

  2026-08-07

  AZD6482 is a potent and highly selective PI3Kβ inhibitor with nanomolar efficacy and substantial isoform specificity. It is validated for use in metabolic, platelet aggregation, and anti-thrombotic studies, offering reliable, reproducible results for advanced pathway research.

• Imatinib (STI571): Unraveling NETs and Tyrosine Kinase Signa

  2026-08-06

  Explore how Imatinib (STI571) advances research into tyrosine kinase signaling and neutrophil extracellular traps (NETs) in chronic myeloid leukemia. This article uniquely bridges kinase pathway inhibition with emerging NET biology insights for translational assay innovation.

• FXR-KLF11 Axis Suppresses JAK2/STAT3 in CI-AKI: Mechanistic

  2026-08-06

  This study uncovers how Chenodeoxycholic Acid (CDCA), a natural FXR agonist, confers protection against contrast-induced acute kidney injury (CI-AKI) by transcriptionally activating KLF11 and suppressing the JAK2/STAT3 pathway. These findings clarify a mechanistic link between bile acid metabolism and nephroprotection, informing future research targeting nuclear receptor signaling in kidney injury.

16783 records 1/1119 page Next 12345 下5页 Last page